Pulmonx (LUNG) Fundamentals 2026 — Revenue Analysis | SniperIQ
Pulmonx (LUNG) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $52M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Pulmonx's market cap?
Pulmonx (LUNG) has a market capitalization of approximately $52M, trading at
What is Pulmonx's P/E ratio?
Pulmonx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Pulmonx?
Pulmonx runs a net profit margin of -60.1%, a gross margin of 75.5%, and an operating margin of -58.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Pulmonx generate?
Pulmonx reported revenue of $90M for fiscal year 2025, with net income of -$54M and earnings per share (EPS) of -1.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Pulmonx pay a dividend?
Pulmonx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Pulmonx financially healthy?
Pulmonx carries a debt-to-equity ratio of 1.23x and a current ratio of 4.91x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Pulmonx a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pulmonx (LUNG) the key facts are: market cap $52M, revenue $90M, 52-week range 1.13-3.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Pulmonx's full fundamentals live
Get Pulmonx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.